Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Genpact's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Genpact's regulatory disclosures and financial reporting.
Genpact Ltd (G) director Tamara Franklin reported a sale of 2,750 common shares at $45.65 on November 12, 2025, according to a Form 4 filing. Following the transaction, she beneficially owns 22,236 shares, held directly. The filing lists a transaction code “S,” indicating a sale, and shows no derivative securities activity reported.
G: A selling holder filed a Form 144 notice to sell 45,703 shares of common stock with an aggregate market value of $2,090,455.22, through Morgan Stanley Smith Barney LLC, with an approximate sale date of 11/13/2025 on the NYSE.
The shares were acquired via a stock option exercise on 11/13/2025 for cash. In the past three months, HEATHER D WHITE reported sales of 4,351 shares for $199,014.74 on 11/12/2025 and 1,039 shares for $45,731.59 on 11/11/2025. Shares outstanding were 172,414,423.
Genpact UK Finco plc and Genpact USA, Inc. plan a primary offering of senior unsecured notes due 2030, fully and unconditionally guaranteed by Genpact Limited and Genpact Luxembourg S.à r.l. The notes pay interest semi-annually beginning in 2026 and rank pari passu with the issuers’ other senior unsecured debt.
The issuers may redeem the notes at any time before one month prior to maturity at a make‑whole price, and at par thereafter; a change of control repurchase event requires a 101% offer to holders. The issuers intend to apply to list the notes on The International Stock Exchange.
Use of proceeds: general corporate purposes, which may include repaying or redeeming the 1.750% senior notes due 2026; approximately $350 million of those 2026 notes are outstanding. As of September 30, 2025, Genpact had $1.2 billion of unsecured indebtedness outstanding and undrawn revolving credit availability of $648.74 million.
Genpact Limited filed an automatic shelf registration (Form S-3) that allows it—and certain subsidiaries as co-issuers—to offer, from time to time after effectiveness, debt securities (with potential guarantees), common shares, preference shares, depositary shares, warrants, and units. Any specific terms and amounts will be set in future prospectus supplements. The company states it may sell directly, through agents, or via underwriters and dealers.
Net proceeds from any future primary offerings will be used for general corporate purposes, which may include acquisitions, debt repayment or refinancing, working capital, and capital expenditures. Genpact’s common shares trade on the NYSE under “G.” Shares outstanding were 172,414,423 as of November 3, 2025; this is a baseline figure, not the amount being offered.
G reported a Form 144 notice indicating a planned sale of up to 2,750 shares of common stock. The filing lists an aggregate market value of $125,537.50 and identifies Morgan Stanley Smith Barney LLC as the broker. The shares are expected to be sold on the NYSE with an approximate sale date of 11/12/2025.
The seller acquired 2,750 shares as restricted stock from the issuer on 12/31/2021 with “Not Applicable” listed for payment terms. Shares outstanding were 172,414,423; this is a baseline figure, not the amount being offered.
Form 144 filing reports a proposed sale of 4,351 common shares with an aggregate market value of $199,014.74. The approximate sale date is 11/12/2025, through Morgan Stanley Smith Barney LLC Executive Financial Services, with the shares listed on the NYSE.
The shares to be sold were acquired on 11/12/2025 via stock option exercise, with cash as the form of payment, in the same amount of 4,351 shares. The filing also discloses activity in the prior three months: Heather D White sold 1,039 shares on 11/11/2025 for $45,731.59.
This notice indicates intent to sell under Rule 144 and includes the required background on acquisition and recent sales.
Form 144 notice: A holder identified as Sameer Dewan filed to sell up to 26,531 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $1,185,999.37 and an approximate sale date of 11/11/2025 on the NYSE.
The shares were acquired from the issuer via equity awards: performance shares and restricted stock granted on 01/10/2021, 01/10/2022, and 01/10/2023, matching the proposed sale amount. Shares outstanding were 172,414,423. Over the past three months, the seller reported a prior sale of 20,078 shares on 08/28/2025 for gross proceeds of $903,510.
Genpact Limited reported higher quarterly results. Net revenues for Q3 2025 rose to $1,291,257 from $1,210,949 a year ago, with income from operations of $191,642. Net income increased to $145,831, and diluted EPS was $0.83 versus $0.74.
For the first nine months of 2025, net revenues reached $3,760,601 and net income was $409,400, with diluted EPS of $2.31. Operating cash flow strengthened to $526,161, supporting buybacks and dividends. Cash and cash equivalents were $740,763 as of September 30, 2025.
The company completed the acquisition of XponentL Data, Inc. for total consideration of $160,157, including $82,657 in cash at closing and an earn-out of $77,500. The deal added customer-related intangibles of $51,400 and goodwill of $112,271. Genpact repurchased 3,919,239 shares year-to-date for $182,905 and paid dividends totaling $88,701. Long-term debt (less current) declined to $827,046, while the current portion rose to $375,871, reflecting near-term maturities.
Genpact Limited furnished an update under Item 2.02, announcing it issued a press release with financial results for the three months ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The information, including Exhibit 99.1, is furnished—not filed—so it is not subject to Section 18 of the Exchange Act and will only be incorporated into other filings if expressly referenced. The company references non-GAAP measures in the release and provides reconciliations to comparable GAAP measures within Exhibit 99.1.
Genpact Ltd (G) reported an equity award to an officer. On 10/10/2025, the Chief Accounting Officer acquired 20,066 common shares at $0, reported as an award of unvested restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Following the transaction, beneficial ownership was 20,066 shares, held directly.
Each RSU converts into one common share upon vesting. The award vests in three equal installments on April 30, 2027, July 31, 2027, and October 31, 2027, subject to continued service through each vesting date.